Acquired Factor V Inhibitor Complicated with Immune Thrombocytopenia
-
- Mima Fuka
- Department of Hematology, Hyogo Prefectural Nishinomiya Hospital, Japan
-
- Minami Ryota
- Department of Hematology, Hyogo Prefectural Nishinomiya Hospital, Japan
-
- Asako Mizuki
- Department of Hematology, Hyogo Prefectural Nishinomiya Hospital, Japan
-
- Matsunaga Hitomi
- Department of Hematology, Hyogo Prefectural Nishinomiya Hospital, Japan
-
- Fujita Yuri
- Department of Clinical Laboratory, Hyogo Prefectural Nishinomiya Hospital, Japan
-
- Takimoto Yoshimi
- Department of Clinical Laboratory, Hyogo Prefectural Nishinomiya Hospital, Japan
-
- Senda Sonoko
- Department of Clinical Laboratory, Hyogo Prefectural Nishinomiya Hospital, Japan
-
- Nakahara Wataru
- Department of Hematology, Hyogo Prefectural Nishinomiya Hospital, Japan
-
- Ikeda Mako
- Department of Hematology, Hyogo Prefectural Nishinomiya Hospital, Japan
-
- Ueda Shuji
- Department of Hematology, Hyogo Prefectural Nishinomiya Hospital, Japan
この論文をさがす
説明
<p>We herein report a patient with a high bleeding tendency as a result of acquired factor V inhibitor and immune thrombocytopenia (ITP). The administration of prednisolone increased the platelet count, but a fatal bleeding event occurred before platelet levels had sufficiently increased. Factor V is stored in not only plasma but also platelets, and platelet-derived factor V might play a local hemostatic role. Bleeding tendency may be high in rare cases where factor V inhibitor is complicated with severe thrombocytopenia. In such patients, physicians should consider aggressive hemostatic therapy, including plasma exchange, in addition to immunosuppressive therapy. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 61 (1), 91-95, 2022-01-01
一般社団法人 日本内科学会
